Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer

Eur J Cancer. 2021 Jul:152:1-3. doi: 10.1016/j.ejca.2021.04.027. Epub 2021 May 28.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Carbamates / administration & dosage*
  • Cetuximab / administration & dosage*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / pathology
  • ErbB Receptors / antagonists & inhibitors
  • Female
  • Humans
  • Mutation
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics
  • Sulfonamides / administration & dosage*
  • Treatment Outcome

Substances

  • Carbamates
  • Sulfonamides
  • encorafenib
  • EGFR protein, human
  • ErbB Receptors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Cetuximab